In order to supplement the company's accumulation of technology and customer base in the innovation sector, improve the industrial layout, and enhance the company's profitability.
.
.
Recently, mergers and acquisitions in the pharmaceutical field have been active
.
According to statistics, since August, 9 A-share pharmaceutical and biological institutions have launched mergers and acquisitions, involving a total amount of over 2.
7 billion yuan
.
For example, on August 10, Huadong Medicine issued an announcement on the acquisition of 60% equity of Wuhu Huaren Technology Co.
, Ltd.
by means of capital increase and equity transfer
.
According to the announcement, Sino-US Huadong will invest a total of no more than 396 million yuan to obtain a 60% stake in Huaren Technology and become its controlling shareholder by means of capital increase and transfer of shares
.
According to the announcement, this transaction is another strong layout of the company's integration into the global pharmaceutical innovation and R&D industry chain, and is highly in line with the company's development strategy for industrial microorganisms
.
The company will aim at international development, closely follow the global industrial microbiology and synthetic biology industry and technology development trends, and create an "industrialized, large-scale and internationalized" industrial cluster
.
Regarding the impact of the above acquisitions on the company, Huadong Medicine stated that the acquisition of Huaren Technology will quickly supplement the company's technical accumulation and customer resources in the above-mentioned fields of industrial microorganism nucleosides, and the existing research and development of industrial microorganisms in nucleosides.
Form effective synergy with industrial layout
.
Dorui Medicine announced on the evening of August 9 that the company signed the "Investment Intention Agreement", and the company plans to transfer 40% of the equity of Bozhou Tianji held by Hubei Tianji
.
Regarding the impact of this acquisition on the company, Dorui Medicine said that the company's investment in Bozhou Tianji will help accelerate the improvement of the company's traditional Chinese medicine industry layout and further enhance the company's profitability
.
On August 8, Grand Pharma also issued an announcement announcing that it has recently entered into an equity acquisition agreement with Hubei Bafeng Pharmaceutical Co.
, Ltd.
% of the equity
.
Regarding the acquisition of Hubei Bafeng, Grand Pharma stated that it is another industrial layout of Grand Pharma in the amino acid sector following the acquisition of Cangzhou Huachen Biotechnology Co.
, Ltd.
in 2021
.
After the acquisition is completed, Grand Pharma will become a pharmaceutical company with many registration numbers of amino acid APIs in the country, expand and improve its product portfolio in the field of high-quality amino acids, consolidate and enhance the comprehensive market competitiveness of the amino acid sector, and at the same time , which will provide a driving force for the sustained and rapid growth of the performance of the amino acid segment
.
Baiyunshan announced on the evening of August 7 that the company plans to purchase 18.
1847% of the company's holding subsidiary Guangzhou Pharmaceutical Co.
, Ltd.
(referred to as "Guangzhou Pharmaceutical") held by Alliance BMP Limited (United Meihua Co.
, Ltd.
) for about 1.
003 billion yuan in cash.
shares
.
Its announcement stated that after the transaction is completed, the company will hold 90.
9237% of the shares of Guangzhou Pharmaceuticals
.
This transaction will help stabilize the equity structure of Guangzhou Pharmaceuticals and continue to promote the development of the company's pharmaceutical distribution business
.
China Resources Pharmaceutical has carried out two acquisitions involving a total amount of more than 800 million yuan
.
China Resources Pharmaceutical announced on August 4 that its subsidiary China Resources Double-Crane Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "China Resources Double-Crane") acquired a 50.
11% stake in Shenzhou Biotechnology for 501 million yuan, and increased its holdings of Tiandong Pharmaceutical with 31.
25% for 307 million yuan.
After the increase in holdings, it will hold a total of 70% of the shares of Tiandong Pharmaceutical
.
In this regard, China Resources Pharma stated that the acquisition of Shenzhou Bio’s equity is expected to help enhance future profitability, realize business layout, quickly enter the field of biological fermentation, improve product acquisition capabilities in the field of biological fermentation, and enrich product pipelines
.
The increase in the holding of Tiandong Pharmaceutical aims to accelerate the integration of resources and promote the rapid development of Tiandong Pharmaceutical, thereby enhancing profitability and comprehensive competitiveness
.
In addition, Shenzhen Microchip Biotechnology announced on August 6 to increase its capital to acquire part of the equity of Chengdu Microchip Pharmaceutical Co.
, Ltd.
with an acquisition amount of 260 million yuan; Guangdong Chenghui Medical announced on August 3 to increase its capital by 15 million yuan to acquire Guangdong Konecranes Part of the equity of Ao Medical Investment Co.
, Ltd.
; Tus Pharmaceutical announced on August 3 to purchase 100% of the equity of Guangdong Xiantong Pharmaceutical Co.
, Ltd.
for 220 million yuan
.
Regarding the frequent mergers and acquisitions in the pharmaceutical industry, some analysts said that through mergers and acquisitions, pharmaceutical companies can avoid repeated construction and disorderly expansion.
The main reasons for mergers and acquisitions are to supplement product lines and extend sales markets
.
